|Bid||7.30 x 200|
|Ask||8.44 x 400|
|Day's Range||7.45 - 7.85|
|52 Week Range||6.99 - 39.86|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.33|
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, is investigating whether Menlo Therapeutics Inc. (“Menlo” or the “Company”) (MNLO) or certain of its officers and directors violated federal securities laws. If you purchased Menlo stock in or after the Company’s January 2018 initial public offering (“IPO”), you are encouraged to contact a Scott+Scott attorney at (844) 818-6982 for more information. Menlo is a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough.
NEW YORK , June 19, 2018 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating whether Menlo Therapeutics ...
NEW YORK, June 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Verizon ...
The Jefferies and JMP conference presentations will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website, www.menlotherapeutics.com, prior to the event. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough. The Company’s clinical development program for serlopitant includes ongoing Phase 2 studies for the treatment of pruritus associated with psoriasis and refractory chronic cough and ongoing and planned Phase 3 studies for the treatment of pruritus associated with prurigo nodularis.
Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various underlying dermatologic conditions and for refractory chronic cough, today announced that data from an exploratory study of serlopitant for the treatment of chronic itch in epidermolysis bullosa (EB) patients was presented by a research team from Stanford University in an oral presentation at the International Investigative Dermatology meeting on May 18, 2018 in Orlando, Florida.
“We continue to make progress on the serlopitant clinical development program. In January, Menlo successfully completed an initial public offering (IPO) of 8,050,000 shares of common stock at a public offering price of $17.00 per share, which included the exercise in full by the underwriters of their overallotment option.
REDWOOD CITY, Calif., May 07, 2018-- Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus associated with various underlying ...
It was a busy week last week in the biotechnology space, with a whole host of companies putting out updates on their respective operations (primarily rooted in development pipelines) and these updates subsequently injecting a considerable amount of volatility into the markets on their release. Here’s a look at some of the biggest movers, what […] The post Here’s What Happened Last Week In Biotech appeared first on Market Exclusive.
NEW YORK, NY / ACCESSWIRE / April 10, 2018 / Negative news about Acadia's Nuplazid drug being a suspect in many adverse event related deaths had Wall Street on edge yesterday, sending shares of the biotech ...
Menlo Therapeutics Inc.(NASDAQ:MNLO) is an early week mover in the biotechnology space this week with the company picking up some volatility on the back of a data-related release. Specifically, and on Monday, Menlo reported some numbers from a phase 2 trial of one of lead development assets and, on the back of the release, has […] The post Is Menlo Therapeutics A Discount Opportunity At Current Pricing? appeared first on Market Exclusive.
Ten weeks into its IPO, Menlo Therapeutics was one of the best-performing offerings, soaring more than 100 percent. On news that its drug flunked a mid-stage trial, the stock fell big.
This Brisbane company is one of the fastest-growing companies in the anti-aging space, focusing on cellular senescence.
The markets may be volatile – but this hasn’t stopped IPOs. According to Renaissance Capital, the first quarter saw the largest amount raised by newly public companies since 2014. In all, 43 companies raised a hefty $15.6 billion.
Here's a look at who may go public in the Bay Area after three IPOs from the region were the best performing in the country in the first quarter.
An East Bay biotech company, attempting to find next-generation ways to stimulate the immune system to fight cancer, raised $120 million in an upsized initial public offering. The IPO from Hayward's Arcus Biosciences Inc. (RCUS) priced at $15 — at the high end of the company's range — as it increased the number of shares available from 7.1 million to 8 million. It is the third IPO among Bay Area life sciences companies this year.
A pair of IPOs from Bay Area companies are expected at the end of the week from Zscaler Inc. and Arcus Biosciences Inc. The one from San Jose-based cloud security company Zscaler is expected Friday and would be the first major tech IPO from the Bay Area since November when San Francisco-based subscription clothing service Stitch Fix Inc. (SFIX) went public. The offering from Arcus Biosciences is the third from a Bay Area biotech, following two at the end of January from Redwood City companies ARMO Biosciences Inc. (ARMO) and Menlo Therapeutics Inc. (MNLO).
The targets have been raised again for what's expected to be the first Bay Area tech IPO in four months. San Jose-based Zscaler Inc. increased the amount of stock for sale and the price targets on its offer, boosting how much it could raise to about $207 million, up 50 percent. It was valued by private investors at a little over $1 billion when it raised its last venture round in the summer of 2015.
Friday's offering from San Jose-based cloud security company Zscaler is set to be the first major tech IPO from the Bay Area since November when San Francisco-based subscription clothing service Stitch Fix went public.
Cloud security unicorn Zscaler Inc. set a price range for its upcoming IPO that would raise up to about $138 million and boost its valuation by about 40 percent. The San Jose company would be valued at around $1.4 billion at the high end of its proposed price range of between $10 and $12 a share. It's in line to be the first major tech IPO from the Bay Area since November when San Francisco-based subscription clothing service Stitch Fix Inc. (SFIX) raised $120 million.
Cloud security unicorn Zscaler Inc. is the most likely candidate to end the Bay Area's latest tech IPO drought. There were only six tech IPOs from the region last year that raised more than $100 million. Uncertainties over the massive tax overhaul and disappointing Wall Street debuts from technology unicorns Snap and Blue Apron were blamed for keeping Valley IPOs down last year, along with IPO-sized late stage funding rounds from investors like Softbank.
CFO software developer Adaptive Insights Inc. is reportedly lining up an IPO. The Palo Alto-based business has hired Morgan Stanley to lead the offering, Reuters said it was told by unnamed sources. Adaptive Insights was launched by Robert Hull in 2003 to build a cloud-based software platform that chief financial officers can use for budgeting, forecasting, reporting, consolidation, dashboards and analytics aimed at finance, sales and other business enterprises.